RPRXvsVTRS
Royalty Pharma PLCvsViatris Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
Royalty Pharma PLC
$49.64
+29.34%
Viatris Inc
$14.75
+26.61%
60-day price, rebased to 100
Round-by-round
Valuation upside
-57.50% vs +97.70% to DCF fair value
Balance-sheet strength
Altman Z 2.25 vs 0.89
Fundamental quality
Piotroski 5.00 vs 4.00 (of 9)
Growth + margins
Rule-of-40 109.80 vs 10.00
60-day momentum
+19.10% vs +13.72% price return
Market-cap liquidity
$27.1B vs $15.6B
Verdict
Across6categories,RPRXtakes the edge with5wins to1. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onRPRXorVTRS
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.